Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DLBG | ISIN: KYG7552D1354 | Ticker-Symbol:
1-Jahres-Chart
YOUNITED FINANCIAL SA Chart 1 Jahr
5-Tage-Chart
YOUNITED FINANCIAL SA 5-Tage-Chart
Actusnews Wire
336 Leser
Artikel bewerten:
(2)

Iris Financial Extends Business Combination Deadline and Amends Articles of Association

Finanznachrichten News

Iris Financial

PO Box 10240

Harbour Place, 103 South Church Street

Grand Cayman

KY1-1002

Amsterdam, the Netherlands - 31 October 2024

Iris Financial - Extends Business Combination Deadline and Amends Articles of Association.

Iris Financial (the "Company") today announced that the deadline of the period in which the Company has to consummate a business combination (the "Business Combination Deadline") has been extended from 2 November 2024 to 31 December 2024 and that certain amendments to the Company's memorandum and articles of association (the "Articles of Association") have been made in order to receive all corporate and regulatory approvals necessary to close the previously announced contemplated business combination with Younited S.A. (the "Combination").

The resolutions to extend the Business Combination Deadline and to amend the Articles of Association were approved by the Company's shareholders at an extraordinary general meeting held on 31 October 2024 (the " EGM").

Shareholders representing 8,100,000 ordinary shares in the share capital of the Company ("Ordinary Shares") submitted a redemption request in connection with the EGM. The redemption requests will be settled in the course of next week.

The Company will convene a separate extraordinary general meeting pursuant to Cayman law to vote, amongst other matters, on the approval of the Combination (the "Business Combination EGM") and will issue a circular, which will include key information regarding the Combination, in connection therewith. Holders of Ordinary Shares who wish to have part or all of their Ordinary Shares redeemed will be given that option again in connection with the Business Combination EGM. Subsequently, an additional extraordinary general meeting will be held pursuant to Luxembourg law, to vote on, amongst other matters, the migration of the Company to Luxembourg.

About Iris Financial

More information about the Company, including the Company's initial public offering prospectus dated 26 April 2022, which was approved by the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten, the "AFM"), can be found on the Company's website http://www.irisfinancial.co.

DISCLAIMER

This announcement contains information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of Regulation (EU) No 596/2014 on market abuse.

This announcement may include forward-looking statements, which are based on the Company's current expectations and projections regarding a business combination, the business, the economy and other future conditions of the Company and speak only as of the date hereof. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "aims", "forecasts", "continues", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy plans, objectives, goals, future events, or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's business, results of operations, financial position, liquidity, prospects, growth or strategies. Forward-looking statements speak only as at the date at which they are made and the Company undertakes no obligation to update these forward-looking statements.

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: xpqekpyZZJzFm3Fwk55umWhpamlokmGbl2KVl2Rta8fJcGqRyW5pbJmYZnFpmmZu
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-88518-iris-financial-press-release-results-extension-egm-final-version-31-october-2024.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.